|
We are excited to share an update
from NeoGenomics that reflects our continued commitment to supporting you
and the patients you treat every day.
We’ve introduced a new vision: A world where every cancer
treatment decision is as personal as the patient. This
reflects the reality of oncology care, and how each patient’s journey is
unique and requires precise, individualized insight. We bring this to
life through testing solutions from our PanTracer portfolio delivering
CGP insights by tissue or liquid biopsy to our MRD assay, RaDaR®
ST, to monitor treatment response and recurrence.
These powerful clinical tools
inspired our new mission statement:
We take cancer
personally. We partner with physicians to deliver actionable insights
that guide treatment decisions and improve outcomes—through a
comprehensive oncology portfolio, integrated customer solutions, and an
unwavering commitment to excellence.
For you, this reinforces what you can
expect from us:
- High-quality,
clinically actionable results
- Timely
insights to support treatment planning and monitoring
- A
comprehensive oncology portfolio across the care continuum
You’ll also begin to see our new
tagline, Answers
are in our DNA, reflecting our focus on delivering
clarity and confidence in every result. This update is less about change
and more about reaffirming our role as a trusted partner in helping you
make informed, personalized treatment decisions for your patients.
|